



6643R5

RECEIVED
FEB 03 2002
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	Examiner: Delacroix Muirheid, C.
Joseph K. Agyin <i>et al.</i>	§	
Serial No.: 09/676,032	§	Group Art Unit: 1614
Filed: September 29, 2000	§	Express Mail No.: EL576204532US
For: Compounds and Methods for Use	§	Customer No.: 030331
Thereof in the Treatment of Cancer	§	
or Viral Infections	§	

Commissioner of Patents
Washington, D.C. 20231

Sir:

AMENDMENT; RESPONSE TO OFFICE ACTION
MAILED NOVEMBER 6, 2001

The present paper is submitted as a complete response to the Official Action mailed November 6, 2001 having a shortened statutory period of response of three months, to and including February 6, 2002. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. The Commissioner is authorized to deduct the fee for a terminal disclaimer (\$110.00) and any other fees under 37 C.F.R. §§ 1.16 to 1.21 that are deemed necessary for the filing of the present document from Procter & Gamble Deposit Account No. 16-2480.

AMENDMENT

In the Specification

At page 16, the second paragraph, starting at line 10, is amended, as indicated below and in the marked up version included with this response as Attachment A:

DNA-interactive agents include alkylating agents, *e.g.*, cisplatin, cyclophosphamide, and altretamine; DNA strand-breakage agents, such as bleomycin; intercalating topoisomerase II inhibitors, *e.g.*, dactinomycin and doxorubicin; nonintercalating topoisomerase II inhibitors, such as etoposide and teniposide; and the DNA minor groove binder plicamycin, for example.